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ABSTRACT
Objective: This systematic review aimed to inform research-
ers and policymakers about what validated outcome mea-
sures are available to evaluate clinical genetics services (CGS)
and the need for new measures.
Methods: Validated outcome measures used to evaluate CGS
were identiﬁed from a systematic literature review. Subjective
outcome measures were assumed to have been validated only
if some form of psychometric assessment was reported.
Results: A total of 1688 titles and abstracts were identiﬁed,
and 61 articles met the inclusion criteria for the ﬁnal review,
which covered 67 validated outcome measures. There were
37 nongenetics-speciﬁc and 30 genetics-speciﬁc measures
identiﬁed. No single validated outcome measure encom-
passed all potential patient beneﬁts from using a CGS. A
variety of different domains were identiﬁed, including
anxiety and depression, coping, decision-making, distress,
family environment, health status, knowledge, mood, per-
ception of risk, perceived personal control, psychological
impact, quality of life, satisfaction and expectations, self-
esteem, spiritual well-being, and worry. Some important
aspects of patient beneﬁt from CGS are not covered by exist-
ing outcome measures.
Conclusions: New research is necessary to develop the array
of outcome measures required to quantify the beneﬁts CGS
offer patients living with the effects of genetic conditions.
These need to be suitable for use in prospective evaluation
studies to provide robust evidence for decision-makers
to inform service development and commissioning. This
includes prioritization of the existing validated outcome mea-
sures in terms of their usefulness and relevance to the mea-
surement and valuation of patient beneﬁts from a CGS.
Keywords: clinical genetics services, decision-making, mea-
surement, outcomes research, systematic review.
Introduction
Clinical genetics services (CGS) have evolved since
they ﬁrst emerged as a medical specialty in the 1970s
[1]. Clinics initially offered clinical diagnosis and coun-
seling services to guide informed decision-making. Ser-
vices have since developed, along with the improved
knowledge and technological advances, to offer genetic
tests for more conditions. With improved understand-
ing of molecular pathways, CGS will be able to offer
improved care pathways with options for managing
and treating genetic conditions. Genetic counseling is
an important part of the overall genetic consultation
and the aspect of the service most apparent to patients.
Genetic counseling involves providing information and
support to patients. Fraser [2] offered a deﬁnition of
genetic counseling that included a number of aspects,
but the key factors were: a communication process so
that the patient can understand the medical facts;
understand the hereditary nature of the condition;
know the options available; and make the best possible
adjustment to the disorder. Genetic testing can form
part of CGS as an aid to genetic diagnosis or to predict
the risk of developing a genetic condition in the future.
The value of the genetic test and associated CGS may
be the individual’s and his or her family’s valuations of
the inherent knowledge of the diagnosis, which can
then act as an aid to decision-making both medically
(e.g., determining future treatment pathways) and per-
sonally (e.g., reproductive decision-making). Ability to
make informed decisions and knowledge of the genetic
condition can be assumed to be key domains to
measure given the role of genetic counseling, speciﬁ-
cally, and CGS, generally.
There has been, and will continue to be, a rapid
expansion in genetics knowledge about the basis of
disease and associated developments in new genetic
tests and CGS [3]. CGS compete with other health-
care services for scarce resources. In this climate of
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expansion, with the potential to impact on National
Health Service (NHS) resources, it is essential to evalu-
ate the impact of new CGS on patients and their fami-
lies. Two main types of outcome measures are used.
Objective clinical measures simply count the number
of times an event occurs and by deﬁnition do not take
account of the patient’s perspective. Subjective mea-
sures quantify an outcome using patient (or clinician)
assessment of an event. Patient-reported outcomes are
inherently subjective, and examples include patient’s
report of a health condition and its treatment, health-
related quality of life, satisfaction with treatment, or
treatment preferences [4].
Clinical genetics services, and associated genetic
testing, are offered as part of health-care services, but
there is a paucity of robust economic evidence that
uses appropriate measures of outcome to support their
use [5,6]. A variety of approaches to outcome mea-
surement in clinical genetics have been attempted over
the past 20 years, none of which have proved adequate
to take account of the full range of the service offered
to patients and their families [7]. It is difﬁcult to
achieve satisfactory measures of outcome and effec-
tiveness in clinical genetics [8]. In view of this, quality
indicators as proxies for outcome measures were advo-
cated until there is more robust evidence [9]. Wang
et al. [7] suggest that outcome measurement is difﬁcult
because the deﬁnition of “success” for genetics services
is rarely stated explicitly. The clinical genetics profes-
sion generally argues that traditional approaches to
outcome measurement in health care will not be rel-
evant or appropriate [10,11]. This is because of the
nature of the problems with which families come to
the genetics clinics and the lack of agreement about the
goals of CGS. This lack of agreement about the goals
of CGS may stem from the fact that there are different
types of services that have developed with speciﬁc
goals in mind. CGS for familial cancers offer patients
information about the risk of developing cancer in the
future and subsequent management and treatment
strategies and as such have different goals from ser-
vices for noncancer-related genetic conditions for
which no treatments are often available.
A number of reviews have called for the develop-
ment of new measures of outcome, and the associated
importance of process measures, for CGS [7,12,13].
The literature to date, however, has not systematically
identiﬁed the breadth of outcome measures applied to
the evaluation of CGS. There has been no structured
approach to identify validated outcome measures that
could be viewed as realistic options for robust,
evidence-based approaches to identify patient beneﬁts
of CGS [7]. This systematic review aimed to inform
researchers and policymakers about what validated
outcome measures are available to evaluate CGS and
the need for new measures. Speciﬁc objectives were to
identify existing validated outcome measures used in
evaluations of CGS and the key domains captured by
these measures.
Methods
Validated outcome measures used to evaluate CGS
were identiﬁed from a systematic literature review. An
outcome measure was deﬁned as “any measured con-
sequence or impact for the patient of using genetics
services.” This systematic review focused on validated
outcome measures, which for the purpose of this
article was deﬁned in terms of whether any form of
psychometric assessment was reported. A CGS was
deﬁned as “a specialist service that offers diagnosis of
genetic conditions; information about genetic condi-
tions including information about inheritance and
risks to family members; genetic testing; and support-
ive counseling to help the family make decisions and
cope better with the genetic condition in their family.
The service is offered to all members of a family in
which a genetic condition may be present, not just
those who have the condition.”
Search Strategy
Electronic searches of MEDLINE (Ovid, 1966 to
date), Embase (Ovid, 1980 to date), PsychInfo (Ovid,
1806 to date), HAPI (Ovid, 1985 to date) and the
Cochrane Library (1900–2005), which includes NHS
Economic Evaluation Database and Database of
Abstracts of Reviews of Effectiveness, were conducted
(February 2006). Figure 1 shows a summary of the key
search terms, which were based on text terms relevant
to outcomes from genetics services. The search strategy
was identiﬁed from consultation with three genetics
health-care professionals, a narrative outcomes review
[7], and a PhD thesis evaluating the genetic counseling
process [10]. Bibliographies of included studies were
checked for relevant articles.
Selection
Three independent reviewers (KP/SN/LMD) screened
identiﬁed studies. Articles were rejected on an initial
screen of titles and abstracts only if the reviewers could
determine that the articles did not meet the inclusion
criteria. If an article could not be rejected with cer-
tainty, the full text of the article was obtained for
further evaluation. The following interventions were
excluded because these interventions are not generally
part of routine CGS: population screening, gene
therapy, and preimplantation genetic diagnosis. In
addition, reviews discussing the implications of the
Human Genome Project, gene patenting, genomics and
commercialization, licensing of genetic testing, storage
of tissue or blood samples, and ethical and legal impact
of genetic testing/services were excluded. This system-
atic review included empirical studies and systematic
reviews of empirical studies that either developed or
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applied outcome measures to CGS. Commentary-type
review studies and studies that did not involve human
subjects or were non-English language articles were
excluded from the review.
Differences in opinion about inclusion were
resolved by discussion within the group and with
others. Articles were included only if they involved an
application of a validated outcome measure to evalu-
ate CGS, using the deﬁnitions assumed by this study.
Assessment and Data Extraction
Assessment of the outcome measure, not the study
design, was the focus of this review. Two main types of
outcomes were deﬁned: objective and subjective mea-
sures. The concept of an objective outcome measure
refers to a measure that quantiﬁes the fact of an event
occurring, such as giving a clinical test, attending a
counseling session, or giving a positive or negative test
result to a patient. Subjective outcome measures refer
to measures that quantify an outcome using patient (or
clinician) assessment of an event. This review only
included subjective outcome measures that had under-
gone some degree of psychometric assessment aimed at
measuring the extent to which the outcome measured
what it claimed to measure. For the purpose of this
article, we refer to these measures as validated mea-
sures if any form of psychometric assessment was
reported. The validation was conﬁrmed only if the
appropriate published primary source, reporting the
psychometric assessments, could be located. Data
extraction forms were used to extract information
about the validated outcome measure and its applica-
tion to CGS. Nonvalidated outcome measures used
were reported but no further details on these measures
were summarized.
Data Synthesis
The primary output of this review was a qualitative
description of validated outcome measures used to
evaluate CGS. Because of the nature of the data col-
lected, they were not synthesized using quantitative
techniques, but extracted data were summarized in
tables and in narrative form.
Results
The search strategy identiﬁed 1668 titles and abstracts.
Of these, 121 full papers were retrieved for further
assessment and 61 papers selected for inclusion in the
ﬁnal review (Fig. 2).
Study Characteristics
The study characteristics for 61 included papers and
the outcome measures used, both validated and non-
validated, are described in the supplementary material
for this article. Three systematic reviews were included
in this review and a fourth systematic review by Bekker
et al. [14] was excluded because the seven studies
referred failed to meet the review inclusion criteria.
Meiser and Halliday [15] and Vadaparampil et al. [16]
clearly reported a list of validated outcome measures
used by the studies identiﬁed in the systematic reviews.
Katapodi et al. [17] reported a set of instruments
for measuring perceived risk to describe emotional
response to breast cancer. The article did not report
each instrument and its validation; therefore, the mea-
sures of perceived risk, and extent of validation for
each measure, could not be reported.
The study designs used in the 61 studies were not
always reported clearly, and in some instances the
study design was deﬁned by the reviewers (KP/SN).
Terms relating to clinical 
genetics services
Examples include:
genetic assessment
genetic evaluation
Terms combined using OR
Terms relating to 
outcome measurement
Examples include:
patient outcome
quality of life
subjective healt effect
decision-making
adjustmentpatient expectation
psychosocial
Terms combined using OR
Examples include:
psychometric
reliability
reproducibility
appropriate
interpretability
Terms combined using OR
Terms relating to 
validation
Terms combined using
AND
Terms combined using
AND
outcome measure
psychological assessment
health status
disability scale
patient preferences
clinical genetics
non-directive counseling
validity
responsiveness
acceptability
precision
feasibility
Figure 1 Summary of key search terms.
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The majority of the studies (37) used only survey
designs, but ﬁve studies used randomized controlled
trials [18–22]; six were before and after studies
[23–28]; and seven used prospective follow-up study
designs [29–35]. Two intervention studies [36,37],
one case-control [38], and three systematic reviews
[15–17] were also reported. The stated aims of the 61
studies varied and included not only studies aimed at
developing a new outcome measure applicable to clini-
cal genetics but also studies using existing validated
outcome measures to evaluate the psychological
impact and psychosocial issues associated with a
variety of CGS.
Validated Outcome Measures
A total of 70 validated outcome measures were
referred to in these 61 studies. Three outcome mea-
sures, Life Coping Skills, the Giessener Complaints
Inventory, and perceived barriers to mammography,
were reported by their authors to have been validated,
but this could not be veriﬁed from a published source
and were therefore excluded from this review. The 67
validated outcome measures were summarized in
terms of the key items or domains assessed, purpose of
the measure, and the extent of validation reported.
(See supplementary material.)
The 67 identiﬁed outcome measures can be broadly
classiﬁed into: 37 nongenetics-speciﬁc (Table 1) suit-
able for the evaluation of any health-care service and
30 genetics-speciﬁc (Table 2). Tables 1 and 2 also show
the number of times each outcome measure was used
in the 61 identiﬁed studies. The majority (n = 46) of
the validated outcome measures were used, and
reported, in just one article, but 21 of the outcome
measures were used on more than one occasion by
various authors. Most of the outcome measures were
used in studies (n = 41) that evaluated CGS for inher-
ited cancers.
The framing of the outcome measures varied, but
generally they presented respondents with a series of
statements that required a rating (63 measures), a true/
false answer (3 measures), or a combination of rating
and a multiple-choice of responses (1 measure). The
Health Orientation Scale is unusual in that is uses a
speciﬁc form of rating scale, the differential scale. A
differential scale differs from a rating scale in that it
does not have a middle or a “neutral” option. Some of
the measures gave results in the form of a single score
or index (28 measures), and some measures gave the
result as a proﬁle that described more than one dimen-
sion (34 measures). Five measures presented the result
as both a proﬁle and an index. None of the measures
were preference-based measures. Preference-based
outcome measures show the weight, or importance,
that individuals attach to changes in health state or
well-being as a result of a health-care intervention.
Critical Assessment of the Outcome Measures
The quality of the reporting and extent of psychomet-
ric assessment of the outcome measures varied. This
review focused on identifying the extent of psychomet-
ric assessment that followed the initial design of an
outcome measure. Table 3 summarizes the extent of
psychometric validation for the 67 outcome measures.
Approximately one-quarter of the outcome measures
(n = 19) were assessed in terms of internal reliability
only. Internal reliability measures the internal consis-
tency of a measure and assesses the extent to which the
1668 potentially relevant articles 
identified via electronic searching
121 papers on outcome measures 
retrieved for more detailed evaluation
61 papers included 
(including 3 systematic reviews)
9236 patients (current or future service users)
1266 health-care staff
3 systematic reviews: 66793 participants
(1) 64,276 (2) not reported (3) 2517
Excluded—reasons:
669 not clinical genetics service
485 not validated outcome
245 not empirical study
10 nonhuman
138 non-English
Excluded—reasons:
4 not clinical genetics service
53 not validated outcome
3 not empirical study
Figure 2 Flow of studies through the system-
atic review.
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items (questions) that relate to a particular dimension
in a scale (e.g., perceived empathy toward patient
stress in the Genetic Counseling Satisfaction scale)
assess only this dimension and no other. The remaining
measures underwent more extensive psychometric
assessment that involved test–retest reliability and
validity but there was limited assessment of sensitivity
to change or interpretability.
Objective Outcome Measures
The review identiﬁed 11 articles that described three
objective outcome measures: accuracy of diagnosis,
accuracy of genetic test results, and rate of termination
of pregnancies. Eleven articles used objective measures
(Table 4) [36,39–48].
Discussion
This systematic review identiﬁed a large body of
evidence describing validated outcome measures, either
Table 1 Nongenetics-speciﬁc outcome measures
Outcome measure Times used
Anxiety and depression
Beck Depression Inventory 5
(Breast) Cancer Attitude Inventory and Anxiety
subscale
1
Cancer Anxiety and Helplessness Scale 1
Center for Epidemiologic Studies Depression-Scale and
brief form
6
Hopkins Symptom Checklist 4
Hospital Anxiety and Depression Scale 8
Self-Rating Depression Scale 1
Spielberger State Trait Anxiety Inventory and state scale
of the Spielberger State Trait Anxiety Index
20
Coping
Utrechtse Coping List 1
Decision-making
Decision Evaluation scales 1
Decisional Conﬂict Scale 1
Distress
Impact of Event Scale 20
Family environment
Family Environment Scale 1
Openness to Discuss Cancer in the Family Scale 1
Health status
Medical Outcomes Short-Form 2
Knowledge
Knowledge about Breast Cancer 1
Knowledge Scale about Breast (and Ovarian) Cancer
and Hereditary
2
Mood
Proﬁle of Mood State 5
Perceived risk
Perceived Risk of Breast Cancer 2
Personality proﬁles
Health Beliefs Model (screening and breast cancer) 1
Life Orientation Test 4
Monitoring Blunting Style Scale, see also Miller
Behavioral Style Scale and Threatening Medical
Situation Inventory
4
Minnesota Multiphasic Personality Inventory plus
supplementary ego strength scale
2
Modiﬁed Tolerance for Ambiguity Scale 2
Psychological impact
Brief Symptom Inventory 4
General Health Questionnaire 6
Global Severity Index of the Symptom Check List-90 3
Psychological Consequences Questionnaire 1
Quality of life
Functional Assessment of Cancer Therapy-General 2
Subjective Quality of Life Proﬁle 1
Satisfaction
Medical Interview Satisfaction Scale—modiﬁed 2
Satisfaction with Decision Scale 1
Self-esteem
Rosenberg Self-Esteem Scale 1
Tennessee Self-Concept Scale 1
Social support
Medical Outcomes Study Social Support Scale 1
Spiritual well-being
Spiritual Well-Being Scale 1
Worry
Breast Cancer Worry 9
Table 2 Genetics-speciﬁc validated outcome measures
Outcome measure Times used
Coping
Psychological Adaptation to Genetic Information Scale 1
Decision-making
Decision-making process 1
Intention to act on shared decision-making program 1
Expectations
Beliefs about Breast Cancer Genetic Testing 1
Prostate cancer genetic screening survey 1
Quality of Care through the Patients’ Eyes 1
Knowledge
Breast Cancer Genetic Counseling Knowledge
Questionnaire
1
Genetic Knowledge Index 1
Knowledge about genetic testing for inherited cancer
(HNPCC and breast cancer)
3
Knowledge about genetic risk for breast cancer 1
Measure of Counselees’ Knowledge of Down
Syndrome
1
Modiﬁed Maternal Serum Screening Knowledge
Questionnaire
1
Risk comprehension and subjective knowledge of
women in the shared decision-making program
1
Outcomes of genetics service
Audit Tool for Genetic Services 1
Perception of risk (beneﬁt)
Assessment of beneﬁts and risk of breast cancer testing 1
Perceptions of the beneﬁts, limitations, and risks of
genetic testing
1
Perceived personal control
Perceived personal control 1
Personality proﬁles
Medical Communication Behavior System 1
Desire to participate in the shared decision-making
program
1
Psychological impact
Anticipated impact of results 1
Emotional reaction to the program information 1
Health Orientation Scale 1
Satisfaction
Genetic Counseling Satisfaction Scale 1
Patient Satisfaction with Genetic Counseling 1
Satisfaction with shared decision-making program 1
Shared decision-making program rationale acceptability 1
Self-esteem
Body Image/Sexuality Scale 1
Worry
Breast cancer (hereditary) concern 1
Multidimensional Impact of Cancer Risk Assessment 1
Worry Interference Scale 1
HNPCC, hereditary nonpolyposis colorectal cancer.
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developed or used to evaluate CGS. Previous systematic
reviews focused on cancer genetics services and
explored different aspects of outcome measures: mea-
sures of perceived risk [17]; measures of psychological
distress; accuracy of perceived risk of developing
cancer; knowledge and screening uptake associated
with cancer [15]; and instruments used to measure
depression, anxiety, and distress in individuals at
increased risk for hereditary breast, ovarian, or colon
cancer [16]. Wang et al. [7] gave an overview of the
potential outcomes from genetics services, including
genetic counseling and genetic testing, and used the
published literature as an illustration. Jarrett and
Mugford [6] critically reviewed the available literature
on published economic evaluations of genetic health
technologies and concluded that methods need to be
developed to consider the value of beneﬁts other than
simple health gain. This article presents the results from
the ﬁrst systematic review to identify and explore the
range of existing outcome measures used across the
broad range of services offered in clinical genetics.
Objective measures quantiﬁed three domains: accu-
racy of diagnosis, accuracy of tests, and rate of termi-
nated pregnancies. Objectives measures, although
relatively easy to apply in practice, may need to be
used in conjunction with other measures that take
more account of the patient’s perspective. It is ap-
parent that a large number of validated subjective
outcome measures have been used to evaluate CGS but
each measure focuses on a restricted number of
domains. The majority of studies have evaluated genet-
ics services for familial cancers, rather than other
genetic conditions, which may reﬂect the type of mea-
sures used. The outcomemeasures usedmost often have
included domains that measure psychological concepts,
such as anxiety, depression, worry, and mood. Gener-
ally, the aim of using such measures was to explore the
psychological impact of receiving the result of a genetic
test, such as breast cancer genes 1 and 2 (BRCA1/2).
Perception of risk was a measure used in a number of
studies [19,20,49]. The systematic review by Katapodi
et al. [17] focused on the relationship between per-
ceived breast cancer risk and breast cancer prevention
and early detection but generally did not report the
extent of psychometric assessment of the measures.
Nearly half of the outcome measures identiﬁed were
bespoke measures designed speciﬁcally for the purpose
of valuing some aspect of the beneﬁts from CGS. With
the exception of the measure of knowledge about
genetic testing for inherited cancers, each of these
bespoke measures was used on one occasion. Impor-
tantly, the extent of psychometric assessment for these
bespoke measures was generally limited and the major-
ity of such measures, approximately 80%, were vali-
dated only in terms of internal reliability measuring
internal consistency using Cronbach’s alpha. This
ﬁnding adds further support to the suggestion that
researchers should look for existing validated mea-
sures ﬁrst before designing their own and not use
unpublished and nonvalidated measures because they
can produce biased results [50]. Approximately one-
quarter of both generic and genetics-speciﬁc measures
were assessed in terms of internal reliability (consis-
tency) only. For the purpose of this article, we included
measures that had any form of psychometric testing.
Nevertheless, it could be argued that using internal
consistency alone is not a sufﬁcient test for complete
validation of a measure to assess the extent to which
the outcome measures the underlying attribute it pur-
ports to measure. The extent of validation of the
majority of the genetics speciﬁc measures and some of
Table 3 Reporting of outcome measure validation
Validation Number of studies
Validity
Face 9
Content 23
Construct 26
Criterion 15
Reliability
Internal 63
Test–retest 25
Sensitivity to change 5
Interpretability 2
Table 4 Studies reporting objective outcome measures
Objective outcome measure Author (Year) Condition
Testing accuracy Ambros et al. (2003) [39] Neuroblastoma
Andersson et al. (1995) [40] Acute intermittent porphyria
Chamberlain et al. (1992) [41] Duchenne and Becker muscular dystrophy
Taylor et al. (2003) [42] Hereditary nonpolyposis colorectal cancer
Diagnosis accuracy Cabana et al. (1998) [43] Ataxia-telangiectasia
Christianson et al. (1995) [44] Termination of pregnancy for abnormality
Park et al. (2002) [45] Hereditary nonpolyposis colorectal cancer
Ward and Jamison (1991) [46] Craniofacial anthropometry
Termination of pregnancy Kim et al. (2002) [47] Sex chromosome abnormality
Kromberg et al. (1999) [36] Huntington disease
Model et al. (2001) [48] Beta thalassemia
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the generic measures identiﬁed in this review was
therefore limited.
There are no examples of measures designed spe-
ciﬁcally to quantify the ability to make informed deci-
sions, but some proxy measures have been used. Brain
et al. used a measure of the decision-making process to
quantify the extent to which women thought or “ago-
nized” about the decision to have a genetic test for
hereditary nonpolyposis colorectal cancer (HNPCC)
[21,51]. Stalmeier et al. [27] devised two measures
centered around decision-making—intention to act on
shared decision-making program and risk comprehen-
sion and subjective knowledge—to evaluate a shared
decision-making program for women with familial
breast cancer. In a more recent study, Stalmeier et al.
used the Decisional Conﬂict Scale to measure how
patients at high risk for breast and ovarian cancer,
awaiting a genetic test result, and facing the choice
between prophylactic surgery or screening, evaluated
their medical treatment choices [52–54].
A number of instruments have been developed to
measure knowledge, which is a necessary but not suf-
ﬁcient component of the ability to make informed
decisions. Measures that assess an individual’s level of
knowledge after a consultation assume that improving
knowledge will facilitate informed decision-making,
but adequate knowledge is only one aspect associated
with making a good decision. The measures of knowl-
edge used to date have mainly been cancer-speciﬁc, for
example, the Knowledge Scale about Breast (and
Ovarian) Cancer and Hereditary [55] and knowledge
about genetic testing for inherited cancer (HNPCC and
Inherited Breast Cancer) [56]. Measures of knowledge
speciﬁc to genetics, rather than cancer genetics, have
also been used in evaluations, such as the Genetic
Knowledge Index [57], Measure of Counselees’
Knowledge of Down Syndrome [58], and the Modiﬁed
Maternal Serum Screening Knowledge Questionnaire
[59]. No existing measures are capable of making the
connection between level of knowledge and the ability
to make informed decisions.
Perceived personal control (PPC) is a concept that
includes domains relating to knowledge, decision-
making, and behavior [60] Berkenstadt et al. designed a
measure of PPC speciﬁcally for use in the evaluation of
genetic counseling [23]. The domain coping has been
included in genetic-speciﬁc measures such as the Psy-
chological Adaptation to Genetic Information Scale
[61] to identify people at risk for coping difﬁculties.
Generic measures, such as the Utrechtse Coping List, a
Dutch adaptation of the Westbrook Coping Scale [62],
were used to evaluate coping strategies to describe
individuals seeking a predictive test for Huntington
Disease [30]. The Openness to Discuss Cancer in the
Family Scale contains domains that are related to a
theoretical model of coping with cancer stress. Van
Oostrum et al. used the Openness to Discuss Cancer
in the Family Scale to explore the long-term psychoso-
cial consequences of carrying a BRCA1/2 mutation
[63,64].
Family issues may be more signiﬁcant than health-
related outcomes when evaluating services aimed to
beneﬁt people with conditions that are inherited and
affect the whole family. As such, family environment
could be a key domain to evaluate CGS, considering
whether using the service had changed the family envi-
ronment of the patient, such as closeness, communica-
tion, and relationships within the family. Biesecker
et al. used the Family Environment Scale, among other
measures, to identify the family variables that charac-
terize members of hereditary breast and ovarian cancer
families who are more likely to choose to undergo
predictive testing after pretest education and counsel-
ing [29,65]. The Family Environment Scale [65] is not
designed to measure patient beneﬁts from a service but
characterize a family environment into one of three
typologies. Van Oostrum et al. used the Openness to
Discuss Cancer in the Family Scale to explore the
impact of carrying a BRCA1/2 mutation in the family
[63]. Other measures that mention the possible impact
on the family include the Beliefs about Breast Cancer
Genetic Testing, measure, which asks about beliefs on
unrestricted ﬂow of information about test results
among family members and physicians [18]. The
Breast Cancer Genetic Counseling Knowledge Ques-
tionnaire assesses knowledge of information provided
during breast cancer genetic counseling and speciﬁcally
asks about knowledge about the implications of
BRCA1/2 status for family members’ risks [66]. No
studies have formally evaluated the impact of CGS on
family environment explicitly.
The interventions offered by CGS often cannot
provide the clear health beneﬁts offered by other
medical services involving pharmacological or surgical
interventions. It is therefore not surprising that generic
measures of health status and quality of life are not
generally used in evaluations of CGS. Cancer genetics is
an exception to this and studies evaluating the impact of
cancer risk evaluation clinics have used the SF-36 to
measure health status [28,67]. Two quality of life mea-
sures have been used in evaluations of CGS. The Func-
tional Assessment of Cancer Therapy-General (FACT)
was designed speciﬁcally for cancer-related quality of
life [68,69]. Schwartz et al. used FACT, along with
other measures, to evaluate the impact of pretreatment
genetic counseling on BRCA1/2 testing and on surgical
decision-making among breast cancer patients at high
risk for carrying a mutation [70,71]. Dazord developed
the Subjective Quality of Life Proﬁle (SQLP) to assess
subjective quality of life in patients or healthy people
and explore the various dimensions of quality of life
[72]. The SQLP was used by Freyer et al. to measure
quality of life of individuals belonging to medullary-
thyroid carcinoma families [73].
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Satisfaction with service is an outcome measure
inextricably linked with the process of how a service is
provided. Measures of satisfaction generally look at
satisfaction with the process of service delivery as a
whole, such as the Medical Interview Satisfaction Scale
[74]. Some measures have been developed speciﬁcally
to evaluate satisfaction with the decision rather than
the process [75]. Quality of Care Through the Patients’
Eyes (QUOTE)-geneCA was designed to measure the
needs and preferences in genetic counseling for heredi-
tary cancer [76]. This measure also incorporates
another key domain related to satisfaction, which is
whether patients’ expectations from using a service
have been met. Satisfaction is a difﬁcult concept to
measure or interpret because it is often not clear what
aspects of the service are driving the observed levels of
satisfaction. It is questionable whether satisfaction is
an outcome measure and may be considered a proxy
outcome measure in that a change in satisfaction may
have an impact on the patient’s health and social well-
being, but this causal link is based on a substantial
assumption.
A number of the measures were designed as predic-
tors of outcome and used to categorize the individuals
using a CGS into a typology of, for example, different
personality traits, rather than using the measure to
value the outcome in terms of the possible patient
beneﬁt from using the service. Biesecker et al. used two
outcome measures that included domains of subjective
well-being, self esteem, and spiritual well-being, in
their description of family variables to characterize
hereditary breast and ovarian cancer family members
who are more likely to choose to undergo predictive
testing [29]. Self-esteem was measured using the
Rosenberg Self-Esteem Scale, and this measure was
originally developed to measure adolescents’ global
feelings of self-worth or self-acceptance [77]. The
Spiritual Well-Being Scale was designed to assess per-
sonal spiritual meaning and satisfaction and deﬁned
spiritual well-being as “the afﬁrmation of life in a
relationship with God, self, community and environ-
ment that nurtures and celebrates wholeness” [78].
These measures were used to describe a person’s char-
acteristics rather than evaluate changes in their char-
acteristics. A number of other studies used measures
that are more accurately described as measuring per-
sonality proﬁles of individuals rather than patient ben-
eﬁts from using a service. Three examples of measures
that can be described as personality proﬁles are the
Monitoring Blunting Style Scale [79], the Minnesota
Multiphasic Personality Inventory [80], and the Life
Orientation Test [81]. Personality proﬁles do not
measure the outcome of the service per se but rather
assess the predisposition of the person using a CGS to
exhibit negative feelings as a result of hearing bad
news and display symptoms of distress, anxiety, or
depression.
Outcome measures for CGS are needed for: 1)
prospective evaluation studies to provide robust evi-
dence for commissioning and service development
decisions; and 2) audits, to identify whether local ser-
vices are effective and of value to patients and 3) to
ensure that service quality is maintained or improved.
The choice of outcome measure depends on the
question being addressed, so a standardized set of
outcome measures is required to meet each of these
possible needs. National decision-making bodies in-
volved in the appraisal of the beneﬁts and cost-
effectiveness of health-care interventions, such as the
National Institute for Health and Clinical Excellence
(NICE), have called for outcome measures that are
generic and preference-based [82]. A generic measure
of patient beneﬁt is necessary to allow interventions
with different effects to be compared directly. Exist-
ing generic health status measures, however, may not
be appropriate to value the potential patient beneﬁts
from using a CGS. Preference-based outcome mea-
sures are necessary to show the weight, or impor-
tance, that individuals attach to changes in health
state or well-being as a result of a health-care inter-
vention. This allows interpretation of the signiﬁcance,
to the patient, of the magnitude of change in a
measure. Outcome measures, such as satisfaction or
knowledge gain, described in this review do not meet
the deﬁnition of a preference-based measure. None of
the outcome measures used to evaluate CGS was
preference-based. If an intervention that forms part
of a CGS were to be appraised by NICE, no outcome
measure is available that meets their suggested
requirements.
Ideally, to be useful in a prospective economic
evaluation that collects cost and outcome data along-
side a randomized controlled trial, as a primary
outcome, the measure should be reported as an index
rather than as a proﬁle. A proﬁle presents an array of
scores for each domain of the outcome measures. Half
of the identiﬁed outcome measures used a proﬁle only.
If an outcome measure is reported as a proﬁle, a
decision-maker must use some subjective judgment
about which domains of the proﬁle are relevant as the
primary outcome. It is methodologically feasible to
convert measures that report proﬁles into indexes by
preference-weighting the dimensions in the measure.
With the exception of the SF-36, this has not been done
for the outcome measures reporting proﬁles identiﬁed
in this review, and further research will be necessary to
produce indexes for use in economic evaluations. In
contrast, a proﬁle measure may be useful as a measure
for use in clinical practice. Each dimension may be
relevant to a different aspect of the service. It will allow
a decision-maker to identify which aspects of the goal
of the service are proving useful.
No single validated outcome measure encompasses
all aspects of the potential patient beneﬁts from using
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a CGS. Individual outcome measures cover speciﬁc
domains in isolation, such as the level of knowledge
about genetic risk for breast cancer or a measure of
PPC. Particular aspects of patient beneﬁts that are
missing from existing measures evaluating CGS
include assessment of the beneﬁts to future generations
that includes some measure of hope in the patient and
other family members [83].
Limitations
Different degrees of psychometric validation were per-
formed and reported, but each measure had some form
of validation to be included in this review. One limi-
tation of this review is the focus on validated outcome
measures, which was a practical decision driven by the
difﬁculties in identifying nonvalidated outcome mea-
sures that may use different nomenclature. Further-
more, excluding the “validation” component of the
search strategy resulted in an unmanageable number of
studies, approximately 29,000, being identiﬁed. Vali-
dated outcome measures are appropriate for robust
evaluations but may exclude potentially useful mea-
sures that contain certain domains relevant to the goals
of a CGS. A further limitation is that only studies
written in the English language were included.
Conclusion
This systematic review has identiﬁed a number of vali-
dated outcome measures and the domains in these
measures. It is clear that no single validated outcome
measure encompasses all aspects of the potential
patient beneﬁts from using a CGS. The focus to date
has been on mainly using measures of psychological
impact, which represents a limited perspective on what
a CGS can offer patients. A variety of different
domains were identiﬁed, but aspects of the potential
patient beneﬁts from using CGS are not being captured
by existing measures. This systematic review did not
ﬁnd sufﬁcient evidence to recommend which of the
existing outcome measures are appropriate to value
the patient beneﬁts from using CGS. Further research
is needed to develop and validate an array of outcome
measures that are capable of quantifying the beneﬁts
CGS offer patients living with the effects of genetic
conditions. It will be necessary to incorporate a variety
of perspectives when designing new measures. Pa-
tients’ views should be used to target the measure to
the aspects of the CGS that beneﬁts them directly.
Health-care professionals’ views may be used to facili-
tate the design of measures that are user-friendly in the
NHS not only for the purpose of evaluation studies but
also for audit of clinical practice. One possible next
step is to prioritize which of the existing validated
outcome measures may be usefully incorporated into
evaluation studies. This review concludes that a core
set of outcome measures may be necessary when evalu-
ating genetics services. This core set of measures,
however, cannot yet be assembled: Gaps identiﬁed in
the range of existing measures suggest possibilities for
future research.
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